(OTCBB: DVBC), (OTCBB: PEFF), (OTCBB: CAMH), (OTC: VASO.OB).

RealPennies.com: Turning Pennies into dollars: (OTCBB: DVBC), (OTCBB: PEFF), (OTCBB: CAMH), (OTC: VASO.OB).

Are you a public company looking for exposure?
Contact RealPennies.com - 1.800.940.6559

For more info: http://dvbc.realpennies.com

Discovery Bancorp (OTCBB: DVBC)(January 28, 2008), parent of Discovery Bank and Celtic Capital, announced yesterday that Frank J. Mercardante has been appointed president, chief executive officer and director of both the holding company and the bank, and a director of Celtic Capital Corp., effective Feb. 1, 2008.

Mercardante is a 40-year veteran of the financial services industry, having most recently served as chairman, president and chief executive officer of Placer Sierra Bank, a $2.7 billion, 50-branch bank headquartered in Sacramento. Placer was sold to Wells Fargo in June 2007. Prior to joining Placer he was a founding director, president and chief executive of Southwest Community Bank headquartered in Carlsbad, Calif., which was sold to Placer in June 2006.

John R. Plavan, chairman of the board of Discovery Bancorp and bank, said, "We are delighted and fortunate to have someone with Frank's track record at the helm of our organization. He has a wealth of experience in the financial services industry and understands the local markets we operate in."

Discovery Bancorp is a bank holding company serving the financial needs of small to medium-sized businesses, professionals and individuals through two principal subsidiaries: Discovery Bank and Celtic Capital Corp. The bank, founded in 2001, has offices in San Marcos, Poway, and Los Angeles, Calif.; Celtic Capital, founded in 1982, maintains offices in Santa Monica, Phoenix, and Bellevue, Wash.

For more info: http://peff.realpennies.com

Power Efficiency Corporation (OTCBB: PEFF)(January 28, 2008), a green energy company focused on efficiency technologies for electric motors, announced it completed its $7.0 million private placement of Units. Insiders, including Steven Strasser, Chairman and CEO, and three other directors, together invested over $1.2 million in the offering.

Steven Strasser, the Company's Chairman & CEO, commented, "We have raised a total of $7.0 million, adding $1.325 million to our previously announced amount. I have decided to invest an additional $80,000 in the Company, bringing my total investment in this round of financing to $880,000. Furthermore, I am particularly pleased that three board members invested a total of $350,000, as previously announced. As I have stated in the past, this level of investment from insiders is an exceptionally strong statement of our belief in the Company's prospects."

Strasser continued, "We are starting this year with over $5 million of capital on the balance sheet and no debt. Our financial capability will allow us to aggressively pursue our business plan."

In the offering, the Company issued 140,000 Units, each unit consisting of one share of Series B Preferred Stock and a warrant to purchase up to 50 shares of the Company's common stock. Each Unit has a purchase price of $50.

Each share of preferred stock is initially convertible into 100 shares of common stock, making the effective common stock purchase price $0.50. The warrants have a per share exercise price of $0.60. The Series B Preferred Stock has an 8% dividend, payable annually in cash or stock, at the discretion of the Company's board of directors. The Series B Preferred Stock has a mandatory conversion clause if the closing price of the Company's common stock averages $1 or greater over a 10 day period.

As previously announced, the total financing included the conversion of $1.85 million in secured notes. In addition, at the initial closing the Company repaid $150,000 in secured notes, plus accrued interest. The notes carried no pre-payment penalty. One half of the warrants issued in connection with the notes vested monthly over the term of the notes, and early repayment resulted in cancellation of approximately 729,000 warrants. Furthermore, elimination of the Company's debt will reduce the Company's interest expenses by $51,000 per month, including $25,000 in cash interest payments and approximately $26,000 in non-cash interest expense.

Power Efficiency Corporation is a green energy company focused on efficiency technologies for electric motors. Power Efficiency is incorporated in Delaware and is headquartered in Las Vegas, Nevada. The Company has developed a patented and patent-pending technology platform, called E-Save Technology, which has been demonstrated in independent testing to improve the efficiency of electric motors by 15-35% in appropriate applications. Electric motors consume over 25% of the electricity in the U.S. and many operate inefficiently. E-Save Technology can be licensed to motor, controls and equipment manufacturers. Power Efficiency's first product based on E-Save Technology is a Motor Efficiency Controller for applications such as escalators, crushers, granulators, mixers, saws, and MG elevators. Power Efficiency is also developing a new product based on E-Save Technology for the tens of millions of small motors found in applications such as residential air conditioning, pool pumps, and clothes dryers. The company is working with manufacturers to incorporate this technology directly into new motors and appliances.

For more info: http://camh.realpennies.com

Cambridge Heart, Inc. (OTCBB: CAMH)(January 28, 2008), announced the resignation of Mark S. Florence from his position as the Company's Vice President of Sales and Marketing. At the same time, the Company announced the appointment of Lamont Baskett and Jim Thompson to Area Vice Presidents of the East and West Regions, respectively.

"I would like to thank Mark for his service and dedication to the Company and wish him well in his new venture," stated Ali Haghighi-Mood, Chief Executive Officer of Cambridge Heart, Inc.

Together, Mr. Baskett and Mr. Thompson have 16 years experience with Cambridge Heart. Both individuals joined the Company as Regional Sales Managers and advanced to senior roles within the Sales organization. Most recently, each held the position of Area Director, managing the direct sales force and working closely with their St. Jude Medical counterparts. Mr. Baskett and Mr. Thompson will report to Cambridge Heart's Chief Executive Officer Ali Haghighi-Mood.

"Lamont and Jim have an excellent understanding of MTWA technology and its role in the cardiology space," stated Ali Haghighi-Mood. "With their combined leadership and experience, I am confident that Lamont and Jim will make significant contributions toward our goal of driving revenue growth".

Cambridge Heart is engaged in the development and commercialization of products for the non-invasive diagnosis of cardiac disease, particularly the identification of those at risk of sudden cardiac arrest. The Company's products incorporate its proprietary Microvolt T-Wave Alternans measurement technologies, coupled with its patented Spectral Analytic Method and ultra-sensitive disposable electrode sensors. Only Spectral Analytic Method MTWA tests are reimbursed by Medicare under its National Coverage Policy that covers patients with a wide variety of cardiac symptoms. Other major insurers in the U.S. also have coverage policies for the test. The T-Wave Alternans test is included in the Guideline for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death jointly developed by the American College of Cardiology (ACC), the American Heart Association (AHA), and the European Society of Cardiology (ESC). The Company, founded in 1990, is based in Bedford, Massachusetts, and is traded on the OTCBB under the symbol CAMH.

For more info: http://vaso.realpennies.com

Vasomedical, Inc. ("Vasomedical") (OTC: VASO.OB)(January 28, 2008), a world leader in the noninvasive treatment of cardiovascular diseases, announced recently that Medicare has increased reimbursement payment rates for EECP therapy for 2008. The new rates, recently published by the Centers for Medicare and Medicaid Services (CMS), are effective immediately for the first six months of 2008 and result in a new national average physician fee payment level of $156.16 per session for EECP therapy --- an increase of 6.2% over the 2007 payment rate. This increase results in a total national average physician fee payment rate of $5,465.60 for a typical 35-hour course of therapy. Changes in the national average physician fee payment for 2008 were a result of the rollback of the planned decrease in the physician dollar conversion factor and an increase in the practice expense portion of the Relative Value Units for EECP therapy.

The national average reimbursement rate for EECP therapy administered in the hospital outpatient setting also increased for 2008 to $109.47 per session, or 2.3% higher than the rate for 2007. This increase results in a national average hospital outpatient payment rate of $3,831.45 for a typical 35-hour course of therapy. Medicare payment rates for physicians and hospitals are adjusted according to a provider's location within the United States.

Dr. John Hui, president and chief executive officer of Vasomedical stated, "Vasomedical will continue to work with CMS towards extending coverage and improving payment rates for this beneficial procedure. It is Vasomedical's goal to continue research and development, and provide the best quality equipment to deliver a safe and effective treatment for cardiovascular disease. As the industry leader, we will also continue to support further clinical research, publication of this data in peer reviewed medical journals and maintain responsible, value-based pricing of our systems, which is necessary to ensure availability and expansion of Medicare and other third-party payer coverage. "

Dr. Hui continued, "In 2008 we expect to see the continuation of published studies, conducted in both U.S. and international EECP treatment facilities, which will help to more clearly demonstrate the benefits of Vasomedical's proprietary EECP therapy for patients with angina, and as a management and preventive treatment for cardiovascular diseases. In addition, this clinical data will help us to promote EECP therapy and expand our market."

Vasomedical, Inc. develops, manufactures and markets EECP therapy systems to deliver its proprietary form of enhanced external counterpulsation therapy. EECP therapy is a noninvasive, outpatient therapy used in the treatment of ischemic cardiovascular diseases, currently used to manage chronic stable angina and heart failure. The therapy increases blood flow and oxygen supply to the heart muscle and other organs and decreases the heart's workload and need for oxygen. Function of the endothelium, the inner lining of blood vessels throughout the body, is also improved, lessening resistance to blood flow. These actions reduce or eliminate symptoms of angina and heart failure, and improve exercise performance and quality of life for thousands of people worldwide.

Read our full disclaimer at: http://www.realpennies.com/start.html
Investors are advised that this analysis is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy. This report does not have regard to the specific investment objectives, financial situation and the particular needs of any specific person who may receive this information. The information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Past performance is no guarantee of future results. Please consult a broker before purchasing or selling any securities mentioned on RealPennies. For more movers: http://www.realpennies.com/wrapup.html

Any opinions expressed herein are statements of our judgment as of the date of publication and are subject to change without notice.
Sitemap: http://www.realpennies.com/sitemap.html

RealPennies .
Telephone: 1-800-940-6559
Matt /at/ realpennies.com